Loading
Engineered Bacterial Therapeutics / Live Biotherapeutic Products · Journal article
Human Vaccines & Immunotherapeutics · August 25, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a multi-database scientometric analysis that mapped 1,730 publications on engineered bacterial therapeutics from 2000–2026, characterizing publication trends, collaboration networks, and thematic evolution in the field. The analysis documents a shift from theoretical synthetic biology toward clinical application areas (probiotics, microbiota therapy, cancer immunotherapy, drug delivery) and identifies persistent translational priorities including controllability, safety, manufacturing consistency, and regulatory alignment. The work is descriptive and does not test clinical or mechanistic hypotheses; it serves to map the knowledge structure and identify research directions rather than to demonstrate efficacy or safety.
Multi-database scientometric (bibliometric) analysis. English-language articles and reviews on engineered bacterial therapeutics, synthetic biology approaches, live biotherapeutic products, engineered probiotics, and bacterial-based therapies indexed in three major databases. n = 1,730. Multi-database search (Web of Science, Scopus, PubMed); analysis identifies China and United States as leading contributors; institutional collaboration noted to be regionally clustered.
1,730 English-language articles and reviews included after screening from initial retrieval of 12,348 records across WoSCC, Scopus, and PubMed Publication output increased steadily with faster growth after 2020; 2025 was the highest-output complete year China and the United States were the leading contributors, although institutional collaboration remained regionally clustered
Descriptive analysis only; does not report efficacy, safety, or outcome data for any therapeutic intervention
This analysis characterizes the publication landscape and research priorities in engineered bacterial therapeutics but does not directly inform clinical decision-making. It may help clinicians, researchers, and regulators understand the maturation of the field toward clinical translation and identify persistent knowledge gaps (controllability, safety, manufacturing, regulatory alignment) that require resolution before widespread clinical adoption.
This is a descriptive scientometric analysis mapping publication trends and collaboration patterns in engineered bacterial therapeutics; it characterizes the field's structure and evolution but does not test a clinical hypothesis or report outcomes data.
As stated by the source record.
Quoted from the source exactly as published.
This analysis characterizes the publication landscape and research priorities in engineered bacterial therapeutics but does not directly inform clinical decision-making. It may help clinicians, researchers, and regulators understand the maturation of the field toward clinical translation and identify persistent knowledge gaps (controllability, safety, manufacturing, regulatory alignment) that require resolution before widespread clinical adoption.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Engineered bacterial therapeutics integrate programmable strain engineering with biomedical functions such as sensing, delivery, immune modulation, microbiome intervention, and disease management. This study conducted a multi-database bibliometric analysis to map the knowledge structure, collaboration patterns, and translational direction of this field. Bibliographic records were retrieved from Web of Science Core Collection, Scopus, and PubMed for publications from 1 January 2000 to 1 June 2026. After document-type filtering, time restriction, deduplication, language screening, and manual eligibility assessment, 1,730 English-language articles and reviews were included. CiteSpace 6.4.R1, VOSviewer 1.6.20, and the bibliometrix R package were used to analyze publication trends, collaboration networks, journal co-citation, dual-map citation trajectories, citation bursts, keyword co-occurrence, and thematic evolution. Publication output increased steadily, with faster growth after 2020; 2025 was the highest-output complete year, while 2026 represented a partial retrieval year. China and the United States were the leading contributors, although institutional collaboration remained regionally clustered. Co-citation, citation-burst, and keyword analyses showed a shift from bacterial chassis construction and circuit design toward engineered probiotics, gut microbiota-related therapy, cancer immunotherapy, drug delivery, live biotherapeutic products, and clinical translation. Persistent translational priorities include controllability, safety, manufacturing consistency, and regulatory alignment.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.